New Deadline for Nitrosamine Impurities

26.03.2020
Risk Evaluation: Extension of Deadline for CEP-Holders until 31.July 20 and for MAH (Marketing Authorisation Holders) until 1.October 2020

The deadline of 26.03.20 to complete step 1 (Risk evaluation) was extended for MAHs and for CEP-Holders due to due to major challenges in meeting the deadlines and due to COVID-19 pandemia.

For further information:



Are you still working on your risk assessment and do you need professional support?

Then, contact us at info@horn-pharma.de.

We know the details of these new requirements. We help you with your CEPs, DMFs and Marketing Authorizations. You can benefit from our long term-experience.


Back

HOTLINE

Phone +49 (0) 7251/305 529
Fax +49 (0) 7251/305 528
Mail

Events

  • 13.-14.07.2020
    Live Online Seminar: Der Regulatory Affairs Manager
    More
  • 25.08.2020
    Frankfurt: Prozessvalidierung - Aktuelle Anforderungen an CMC-Daten
    More
  • 06.-07.10.2020
    Vienna: Change Control – New Aspects and Best Practices
    More
Get all events



News

  • 18.05.2020
    Impact of COVID-19 pandemic on Pharma: GMP and Regulatory Flexibility
    More
  • 26.03.2020
    New Deadline for Nitrosamine Impurities
    More
  • 24.03.2020
    News on Nitrosamine Impurities
    More
Get all news
EU: New Variation System in force as of Jan 1, 2010. Filing of variations will be faster, easier, and more flexible. Have you considered that your Change Control System needs to be updated accordingly?
EU: Centralised Marketing Authorisation Procedure for ATMPs needed Have you already filed your application? The time clock is ticking. Transitional periods will be over soon.
This website uses cookies. By using the website you agree to the use of cookies. Privacy Policy X